DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20201189

## **Original Research Article**

## Pattern of adverse drug reactions reported at a tertiary care teaching hospital in northern India

Arpita Singh<sup>1</sup>, Atul Jain<sup>1\*</sup>, Maneesh Soni<sup>2</sup>, Pooja Shukla<sup>1</sup>, Joonmoni Lahon<sup>1</sup>, Ajay Kumar Verma<sup>3</sup>

<sup>1</sup>Department of Pharmacology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India <sup>2</sup>Pv Associate, NCC-PvPI, IPC, Ghaziabad, Uttar Pradesh, India

<sup>3</sup>Department of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India

Received: 28 January 2020 Revised: 09 March 2020 Accepted: 11 March 2020

\***Correspondence:** Dr. Atul Jain, Email drjainatul1@gmail.com

**Copyright:** © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

## ABSTRACT

**Background:** Adverse drug reactions (ADRs) are among the leading cause of morbidity and mortality in hospital setup. This study was conducted with the aim of understanding the pattern and occurrence of ADRs to minimize their risk and safeguard public health.

**Methods:** This study is a retrospective analysis of pattern of ADRs reported at ADR monitoring centre (AMC) in a tertiary care hospital. A total of 207 spontaneous ADR reports collected over a period of 18 months were analysed for pattern and type of reactions, demographic profile of patients, organ system affected by ADRs, causative drugs, route of drug administration, severity of reaction, their outcome, management and causality assessment.

**Results:** Most common age group affected by ADRs was 41-50 years with almost equal involvement of male and female gender. Cutaneous reactions involving skin like rashes and itching were most common ADRs. The most common causative drug for ADRs were antimicrobials agents like Penicillin and Cephalosporin group of antibiotics. Orally administered drugs were most commonly involved in causing ADRs. Most of the ADRs belonged to Type A category, were non-serious and moderate in severity. Most of the patients recovered from the ADRs on stopping the suspected drug. On assessing the causality, most of the ADRs were probable with the suspected drugs.

**Conclusions:** Most of the patients recover from ADRs with appropriate and timely intervention, but it is important to understand the pattern and occurrence of ADRs for patient safety and this is possible only with an effective and robust pharmacovigilance system.

Keywords: Adverse drug reaction, AMC, Causality assessment, Pharmacovigilance

## **INTRODUCTION**

Medicines are intended for treatment and better outcome but still there are possibilities of occurrence of adverse drug reactions. Adverse drug reaction is defined as "a response to a medicine which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of the disease or for the modifications of physiological function."<sup>1</sup> According to various studies, adverse drug reactions are one of the leading causes of morbidity and it accounts for a significant number of hospital admissions in India and worldwide. A study in India reported overall incidence of 9.8% ADRs including 3.4% of total hospital admissions and 3.7% ADRs developed during hospital stay.<sup>2</sup> Hence, understanding the benefit and risk of drug therapy is necessary for which an effective nationwide pharmacovigilance system is essential. Pharmacovigilance (PV) is defined by the WHO as "the science and activities relating to the detection, assessment, understanding and prevention of adverse other drug-related problem".<sup>3</sup> effects or any Pharmacovigilance Programme of India (PvPI) was operationalized in July, 2010 by Ministry of Health and Family Welfare, Government of India. The AIIMS, New Delhi was established as National Coordination Centre (NCC) for PvPI. 22 ADR Monitoring Centres (AMCs) had been set up under this programme. In 2011, NCC was shifted to Indian Pharmacopoeia Commission (IPC), Ghaziabad. During last 7 years PvPI has collaborated with several national health programmes and research institutions and the number of AMCs (ADR Monitoring Centres) has increased to more than 250. In 2017, the Pharmacovigilance Programme of India (PvPI)- Indian Pharmacopoeia Commission (IPC), in Ghaziabad, India, became a WHO Collaborating Centre.<sup>4</sup> Since there exist considerable social and economic consequences of adverse drug reactions, there is a need to engage healthcare professionals and the public at large, in a wellstructured programme. The vision of PvPI is to improve patient safety and welfare in Indian population by monitoring drug safety and thereby reducing the risk associated with use of medicines.5 Our AMC (adverse drug reaction monitoring centre) is designated under PvPI and is working for the safety and welfare of patients by early detection, reporting and monitoring of ADR in hospital setup and by providing its prompt and appropriate management. This is a retrospective study done to analyze the ADR reported at our AMC to know the type and pattern of ADR reported, demographic profile of patients, organ system involved, causative drugs, severity, outcome, management and causality assessment, in view of improving health safety of patients.


#### **METHODS**

All the ADR reported in the study duration were included in this study. The ADRs were collected from various departments at our AMC, on the "suspected adverse drug reaction reporting form" from the health care professionals, as prescribed by IPC.<sup>6</sup> Causality for ADRs were assessed according to WHO Uppsala Monitoring Centre (UMC) Causality Assessment Criteria.<sup>7</sup> The Pv associate at our AMC then uploads the reports in Vigiflow software and send it to NCC, IPC Ghaziabad which is further send after analysis to Uppsala Monitoring Centre, Sweden for maintaining ADR database, further analysis and signal detection.<sup>8</sup>

A total of 207 suspected ADR reports were received from various department at our AMC from September 2017 to February 2019. These reports were analysed retrospectively for the demographic profile of patients, type and pattern of ADRs, causative drugs, severity of ADRs, their outcome, management and causality assessment. This study was done after getting ethical clearance from the Institutional Ethics Committee, strict confidentiality was maintained about the particulars of involved patients during the study. Data analysis was done using descriptive statistical analysis.<sup>9</sup>

### **RESULTS**

The age group most commonly involved with ADRs was in the range of 41-50 years (n=44, 21.25%) followed by 51-60 years (n=39, 18.84%) and then 21-30 years (n=38, 18.35%). The gender distribution was almost equal for both males (n=104, 50.25%) and females (n=103, 49.75%) as shown in Figures 1 and 2.








Figure 2: Gender distribution.

Cutaneous ADRs (n=92, 44.44%) involving skin like rashes and itching were the most common ADRs reported by various departments. This is followed by generalized ADRs (n=52, 25.12%) like whole body discomfort, chills and rigors, and then gastrointestinal ADRs (n=20, 9.66%) like vomiting, abdominal pain, and diarrhoea (Table 1).

The drugs involved most commonly with ADRs were Antimicrobial agents (n=62, 29.95%) belonging to Penicillin and Cephalosporin group, followed by drugs acting on central nervous system (n=41, 19.80%) like

Antiepileptics and Antidepressants which is then followed by Anti-cancer drugs (n=24, 11.59%) like Paclitaxel and Rituximab (Table 2).

## Table 1: Pattern of ADRs involving different organ systems.

Cutanous(44.44 %)Skin rashes61Iching16Skin inflammation7Hyperpignentation2Exfoliation2Ecolymotic patches1Thrombophlebitis1Stevens Johnsons syndrome1Fingles on face1Generalised MDR52 (25,12%)Chills and rigors16Body discomfort15Generalised Welling9Dizzines4Weakness3Lymphadenopathy1Muscle Cramps1Generalised MDR1Generalised Mark1Generalised Mark1Generalised Mark1Goldices3Lymphadenopathy1Muscle Cramps1Gidlices1Generalised Mark20 (9,66%)Vomiting5Dizrinetstinal ADRs20 (9,66%)Vomiting1Sasea1Lipatifis2Nausea1Controlestinal ADRs2Steepiness4Selepiness1Selepiness1Selepiness1Selepiness1Selepiness1Selepiness1Selepiness1Selepiness1Selepiness1Selepiness1Selepiness1Selepiness1Selepiness1Selepiness1Selepiness <t< th=""><th>ADRs</th><th>Value</th></t<>	ADRs	Value
Skin rashes61liching16Skin inflammation7Hyperpignentation2Exfoltation2Exclonation1Thrombophetbitis1Thrombophetbitis1Stevens Johnsons syndrome1Pimples on face2Generalised ADR52 (25.12%)Chills and rigors16Body disconfort15Generalised swelling9Dizziness3Veakness3Lymphadenopathy1Generalised inflammation1Gidminess1Generalised inflammation1Gidminess20.96%)Voaniting5Diarhoea1Gastroinsteinal ADRs20.96%)Voaniting1Gastroinstein1Cistifies		
Inching16Skin inflammation7Skin inflammation2Exclution2Exclution2Exclution1Thrombophlebitis1Stevens Johnson syndrome1Pimples on face1Generalised ADR52 (25 12%)Chills and rigors16Body discomfort15Generalised welling9Dizzines4Weakness3Lymplacenopathy1Muscel cramps1Generalised welling9Dizzines4Weakness3Stormet and the syndrome1Gidliness1Generalised welling1Gidliness1Generalised welling20 (9.66%)Vomiting5Abdominal pain5Diarrhoea4Hepaticis1Difficulty in eating and drinking1Central errows system ADRs1Stechton<		· · · · · · · · · · · · · · · · · · ·
Skin inflammation7Hyperpignentation2Excloitation2Excloitation1Thrombophelbitis1Stevens Johnsons syndrome1Pimples on face1Generalised ADR52 (25.12%)Chills and rigors16Body disconfort15Generalised ADR2 (25.12%)Chills and rigors16Body disconfort15Generalised ADR2 (25.12%)Chills and rigors1Generalised ADR2Question3Lymphadenopathy1Muscle cramps1Generalised inflammation1Generalised inflammation1Generalised odema1Generalised odema1Generalised odema20 (9.66%)Vomiting5Abdominal pain5Diarboca4Hepatitis2Loss of appetite1Officulty in eating and drinking1Gastritis1Generalised odema1Central nervous system ADRs12 (5.79%)Silfenses12 (5.79%)Palpitation1Hepatension1Ingling2Trenors1Stiffness10 (4.83%)Dysponea7Chertal nervous system ADRs10 (4.83%)Dysponea7Chertal odepenia3Panyotopenia3Panyotopenia3Panyotopenia3 <td></td> <td></td>		
Hyperpigmentation2Extoliation2Exclanation1Thrombophlebitis1Stevens Johnson syndrome1Pimples on face1Generalised ADR52 (25 12%)Chills and rigors16Body discomfort15Generalised swelling9Dizziness4Weak ness3Lymphalenopathy1Muscle cramps1Generalised ordema1Generalised ordema1Generalised ordema1Generalised ordema1Generalised ordema1Generalised ordema1Generalised ordema1Generalised ordema1Generalised ordema1Gastrointestimal ADBs20 (9.6%)Vorniting5Abdominal pain5Diarrhoea4Hepatitis1Loss of appetite1Difficulty in eating and drinking1Gastrinitis1Central nervous system ADBs1Stelphense2Tremots1Stiffness1Hypertension1Hypertension1Respiratory system ADBs10 (4.83%)Pysproze7Chest pain2Hematological ADBs10 (4.83%)Pysproze7Chest pain2Hematological ADBs3 (1.44%)Hypertricaemia2Hematological ADBs10 (4.83%)		
Exfoliation2Ecchymotic patches1Ihromolophichitis1Stevens Johnsons syndrome1Pimples on face1Generalised ADR52 (25.12%)Chills and rigors16Body disconfort15Generalised swelling9Dizziness3Weakness3Lymphadenopathy1Muscle cramps1Generalised inflammation1Generalised odema1Generalised odema1Generalised odema1Generalised odema20 (9.66%)Vomiting5Abdominal pain5Diarrhoea1Hepatitis2Nusse1Central nervous system ADRs13 (6.28%)Steprines4Sedachae2Tremors1Ifficulty in eating and drinking1Steprines4Sedachae2Tremors1Ifficulty on eating and drinking1Steprines4Sedachae2Tremors1Ifficulty on eating and drinking1Steprines4Sedachae2Tremors1Ingling2Steprines4Sedation1Steprines1Steprines1Steprines1Steprines1Steprines1Steprines1Steprines3		
Ecchymotic patches1Thrombophiebitis1Stevens Johnsons syndrome1Pimples on face1Generalised ADR52 (25.12%)Chills and rigors16Body discomfort15Generalised swelling9Dizziness4Weakness3Lymphadenopathy1Muscle cramps1Generalised swelling1Generalised stream1Giddiness1Giddiness1Gastrointestinal ADRs20 (9.66%)Vomiting5Joirrhoea4Hepatitis20Abdominal pain5Difficulty in eating addinking1Gastrointestinal ADRs20Vomiting5Joirrhoea1Loss of appetite1Difficulty in eating and drinking1Gastrointestinal ADRs2Steepiness4Portificulty in eating and drinking1Gastrointestinal ADRs2Steepiness4Loss of appetite1Difficulty in eating and drinking1Gastritis1Centra nervous system ADRs1Steepines1Steepines1Palpitation1Hypertension1Hypertension1Resprintory system ADRs10 (4.83%)System ADRs3 (1.44%)Hypertension3Panettopenia3Panettopenia<		
Thromophlebiais1Stevens Johnson syndrome1Finples on face1Generalised ADR52 (25.12%)Chills and rigors16Body disconfort15Generalised swelling9Dizziness4Weakness3Lymphadenopathy1Muscle cramps1Generalised inflammation1Generalised onflammation1Generalised onflammation1Generalised onflammation20 (9.66%)Vormiting5Abdominal pain5Diarrhoea4Hepatitis20Loss of appetite1Difficulty in eating and drinking1Central nervous system ADRs2Steppiness4Sedation2Tinging2Thermors1Cardrovacular ADRs2Soldion2Stiffness1Ingling2Thermors1Stiffness1Cardrovacular ADRs2Stiffness1Thermors1Stiffness1Palpitation1Hypertension7Chest pain2Henatoolgied ADRs3Stiffness3Cardrovacular ADRs2Stiffness3Lower and adving		
Steven Johnsons syndrome1Pimples on face1Generalised ADR52 (25.12%)Chills and rigors16Body discomfort15Generalised Swelling9Dizziness4Weakness3Lymphadenopathy1Muscle cramps1Generalised Inflammation1Giddiness1Generalised inflammation1Generalised oedema1Gentrolised Jones20 (9.66%)Vorning5Abdominal pain5Diarrhoea4Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Gastroit Strostens13 (6.28%)Steedation2Tremots1Stiffness1Cardiovascular ADRs1Steedation2Tremots1Stiffness10 (4.83%)Dyspona7Chardiaget ADRs3 (1.44%)Thrombocytopenia3Papetration1Respiratory system ADRs3 (1.44%)Thrombocytopenia3Papetration1Experimentian1Respiratory system ADRs3 (1.44%)Hyperuricaenia1Cardiovascular ADRs3 (1.44%)Hyperuricaenia2Urennia1Experimentian1Respiratory system ADRs3 (1.44%)Hyperuricaenia1 <t< td=""><td></td><td></td></t<>		
Pimples on face1Generalised ADR52 (25.12%)Chills and rigors16Body discomfort15Generalised swelling9Dizziness4Weakness3Lymphadenopatly1Muscle cramps1Generalised inflammation1Generalised codema1Generalised codema1Generalised codema1Generalised codema1Generalised codema20 (9.66%)Vomiting5Abdominal pain5Diarrhoca4Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Gentral nervous system ADRs3 (6.28%)Sleepiness4Sedation2Tingling2Headache2Palpitation11Hypernsion1Ruspretnesion1Stiffness1Headache2Stiffness1Headache2Syspoca7Chest pain3Auspretnesion3Palpitation1Hypernsion3Resprintory system ADRs3 (1.44%)Thrombocytopenia3Panetologiel ADRs3 (1.44%)Hypernricemia2Uremia1Eudocine system ADRs3 (1.44%)Hypernricemia2Uremia1Eudocine system ADRs3		
Generalised ADR52 (25.12%)Chills and rigors16Body disconfort15Generalised swelling9Dizziness4Weakness3Lymphadenopathy1Muscle cramps1Generalised inflammation1Generalised odema1Generalised odema1Gentrelisted odema20 (9.66%)Vorniting5Diarrhoea4Hepatitis20 (9.66%)Vorniting5Diarrhoea4Hepatitis2Castrofitis1Contral paria5Diarrhoea1Loss of appetite1Difficulty in eating and drinking1Gastrifitis1Central nervous system ADRs3 (6.28%)Sleepiness4Sedation2Tremors1Stiffness1Cardiovascular ADRs10 (4.83%)Dyspnoca7Chest pain3Palpitation1Hypertension2Respiratory system ADRs10 (4.83%)Dyspnoca7Chest pain3Palpitation1Hematological ADRs3 (1.44%)Uremia1Lendor: esytem ADRs1 (0.48%)		
Chills and rigors16Body disconfort15Generalised swelling9Dizziness4Weakness3Lymphadenopathy1Muscle cramps1Generalised inflammation1Generalised inflammation1Generalised inflammation1Generalised inflammation1Generalised ocdema1Generalised ocdema1Generalised ocdema1Gastrointestinal ADRs20 (9.66%)Vorniting5Abdominal pain5Diarhoea4Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Gastritis1Central nervous system ADRs3 (6.28%)Stelepiness4Sedation2Tremors1Stiffness1Cardiovascular ADRs12 (5.79%)Palpitation1Hypernesion1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs3 (1.44%)Thrombocytopenia3Pancytopenia3 (1.44%)Hyperncaemia2Uremia1Eudorine system ADRs1(0.48%)		
Body disconfort15Generalised swelling9Dizziness4Weakness3Lymphadenopathy1Muscle cramps1Generalised inflammation1Giddiness1Generalised odema1Generalised odema1Gastrointestinal ADRs20 (9.66%)Vomiting5Abdominal pain5Diarhoea4Hepatitis2Nausea1Cost of appetite1Difficulty in eating and drinking1Gastritis1Stelpness4Sedation2Tingting2Headache2Tremors1Stiffness1Cardiorascular ADRs1Stiffness1Headache2Tremors1Stiffness10 (4.83%)Dyspnoca7Cherts pain2Henatological ADRs1Styppenia3Papitation1Henatological ADRs3Orsenanting3Papitotion3Thrombocytopenia3Papitation1Henatological ADRs3Uremia1Lendering worth ADRs1Lendering worth ADRs1Cardiorascular ADRs2Uremia1Endering worth ADRs3Uremia1Lendering worth ADRs3Uremia<		
Generalised swelling9Dizziness4Weakness3Lymphadenopathy1Muscle cramps1Generalised inflammation1Giddiness1Generalised odema1Gastrointestinal ADRs20(9.66%)Vomiting5Abdominal pain5Diarnhoea4Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Gastrointestinal ADRs2Selepiness4Selepiness3Siffiness1Stiffness1Central nervous system ADRs13 (6.28%)Siffiness1Cardionaceular ADRs2Siffiness1Cardionaceular ADRs2Siffiness1Stiffness1Stiffness1Stiffness1Number ADRs10 (4.83%)Dyspneea7Chest pain3Approxema ADRs4 (1.93%)Dyspneea3Sharthole ADRs3 (1.44%)Thrombocytopenia3 (1.44%)Hypertracemia2Uremia1Educrine system ADRs3 (1.44%)		
Dizziness4Weakness3Lymphadenopathy1Muscle cramps1Generalised inflammation1Giddiness1Generalised oedema1Gastrointestinal ADRs20 (9.66%)Vomiting5Abdominal pain5Diarrhoea4Hepatitis2Nausca1Loss of appetite1Difficulty in eating and drinking1Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Tremors1Stiffness1Cardiovascular ADRs12 (5.79%)Palpitation1Hypertension1Hypertension2Hematological ADRs3 (1.44%)Dysnoea3Pancytopenia3Pancytopenia3 (1.44%)Hypertracemia2Uremia1Respiratory system ADRs3 (1.44%)		
Weakness3Lymphadenopathy1Muscle cramps1Generalised inflammation1Giddiness1Generalised oedema1Gastrointestinal ADRs20 (9.66%)Vomiting5Abdominal pain5Diarrhoea4Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Gestrointest4Selepiness4Selepiness4Selepiness1Stiffness1Cardiovascular ADRs1Stiffness1Ingling2Headache2Tremors1Stiffness1Ingling1Respiratory system ADRs10 (4.83%)Systema1Cardiovascular ADRs1Ingling2Headache2Tremors1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia3 (1.44%)Hypertracemia2Urernia1Educerine system ADRs1 (0.48%)		
Lymphadenopathy1Muscle cramps1Generalised inflammation1Giddiness1Generalised oedema1Gastrointestinal ADRs20 (9.66%)Vorniting5Abdominal pain5Diarthoea4Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tremors1Stiffness1Itersion1Respiratory system ADRs1Stiffness1Chest pain1Chest pain1Respiratory system ADRs1Stiffness1Chest pain2Henatological ADRs10 (4.83%)Dysnoea3Pancytopenia3Pancytopenia3Pancytopenia3Henatological ADRs-3 (1.44%)Hypertricaenia2Uremia1Endocrine system ADRs1 (0.48%)		
Muscle cramps1Generalised inflammation1Giddiness1Generalised oedema1Gastrointestinal ADRs20 (9.66%)Vomiting5Naterial ADRs20 (9.66%)Vomiting5Diarrhoea4Hepatitis2Loss of appetite1Difficulty in eating and drinking1Officulty in eating and drinking1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Tremors1Stiffness1Stiffness1Happettension1Hypertension1Hypertension1Thrombocytopenia3Pancytopenia3Anacolegical ADRs3 (1.44%)Hypertricaemia3 (1.44%)Hypertricaemia2Uremia1Edocrine system ADRs1 (0.48%)		
Generalised inflammation1Giddiness1Generalised odema20 (9.66%)Voniting5Abdominal pain5Diarrhoea4Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Geatroine system ADRs3 (6.28%)Steapines4Sedation2Tingling2Headache2Tremors1Stiffness1Stiffness1Hypertension1Hypertension1Thrombocytopenia3Panytopenia3Thrombocytopenia3Renal system ADRs-3 (1.44%)Hypertricaemia3Uremia1Internological ADRs-3Internological ADRs-3<		
Giddiness1Generalised oedema1Gastrointestinal ADRs20 (9.66%)Vomiting5Abdominal pain5Diarrhoea4Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tremors1Cardiovascular ADRs12 (5.79%)Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Opsproa7Chest pain3Appendix3Thrombocytopenia3Pancytopenia3Henatological ADRs-3 (1.44%)Hypertricaemia2Uremia1Locarcine system ADRs-1 (0.48%)		
Generalised oedema1Gastrointestinal ADRs20 (9.66%)Vomiting5Abdominal pain5Diarrhoea4Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Headache2Tremors1Cardiovascular ADRs12 (5.79%)Palpitation1Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain3Pancytopenia3Pancytopenia3Pancytopenia3 (1.44%)Hypertricarenia2Uremia1Endocrine system ADRs1 (0.48%)		
Gastrointestinal ADRs20 (9.66%)Voniiting5Abdominal pain5Diarthoea4Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Headache2Tremors1Stiffreuss1Cardiovascular ADRs12 (5.79%)Palpitation1Hypertension10 (4.83%)Dyspnea3Panological ADRs3Panotogical ADRs3 (1.44%)Hypertracennia3Pancytopenia3Pancytopenia3Hypertracennia1Hypertracennia1Hypertracennia1Hypertracennia1Hypertracennia1Hypertracennia1Hypertracennia1Hypertracennia1Hypertracennia1Horennia1Hypertracennia1Hypertracennia1Hypertracennia1Hypertracennia1Hypertracennia1Horennia1Hypertracennia1Hypertracennia1Hypertracennia1Hypertracennia1Hypertracennia1Hypertracennia1Hypertracennia1Hypertrac		
Vomiting5Abdominal pain5Diarthoea4Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Headache2Tremors1Cartoiovascular ADRs12 (5.79%)Palpitation1Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain3Pancytopenia3Pancytopenia3Pancytopenia3 (1.44%)Hypertricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Abdominal pain5Diarrhoea4Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Headache2Tremors1Stiffness1Cardiovascular ADRs1Sliffness1Pappetension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain3Paneytopenia3Paneytopenia3Paneytopenia3Puppetricaemia2Uremia1Endocrine system ADRs1 (1.48%)		
Diarrhoea4Hepatitis2Nausea1Loss of apetite1Difficulty in eating and drinking1Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Headache2Tremors1Stiffness1Cardiovascular ADRs1Stiffness1Hypertension1Hypertension1Respiratory system ADRs10 (4.83%)Dyspoca2Thrombocytopenia3Pancytopenia3Pancytopenia3 (1.44%)Hyperturiaemia1Uremia1Endocrine system ADRs1 (0.48%)		
Hepatitis2Nausea1Loss of appetite1Difficulty in eating and drinking1Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Headache2Tremors1Stiffness1Cardrovascular ADRs1Stiffness1Cardiovascular ADRs1Palpitation1Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs3Pancytopenia3Pancytopenia3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Nausea1Loss of appetite1Difficulty in eating and drinking1Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Headache2Tremors1Stiffness1Cardrovascular ADRs1Palpitation1Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs3Pancytopenia3Pancytopenia3 (1.44%)Hyperuniaemia1Lensina1Itemato3Pancytopenia3 (1.44%)Hyperuniaemia1Lensina1 (0.48%)		
Loss of appetite1Difficulty in eating and drinking1Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Headache2Tremors1Stiffness1Cardiovascular ADRs12 (5.79%)Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs3Parcytopenia3Parcytopenia3Parcytopenia3 (1.44%)Hypertricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Difficulty in eating and drinking1Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Headache2Tremors1Stiffness1Cardiovascular ADRs12 (5.79%)Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Gastritis1Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Headache2Tremors1Stiffness1Cardiovascular ADRs12 (5.79%)Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs3Pancytopenia3Pancytopenia3 (1.44%)Hypertricaemia2Uremia1Itali3Itali		
Central nervous system ADRs13 (6.28%)Sleepiness4Sedation2Tingling2Headache2Tremors1Stiffness1Cardiovascular ADRs12 (5.79%)Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Dyspoea7Chest pain2Hematological ADRs3Pancytopenia3Pancytopenia3Ithrombocytopenia3 (1.44%)Hypertricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Sleepiness4Sedation2Tingling2Headache2Tremors1Stiffness1Cardiovascular ADRs12 (5.79%)Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs3 (1.44%)Thrombocytopenia1Renal system ADRs-3 (1.44%)Hypertricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Sedation2Tingling2Headache2Tremors1Stiffness1Cardiovascular ADRs12 (5.79%)Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Tingling2Headache2Tremors1Stiffness1Cardiovascular ADRs12 (5.79%)Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Headache2Tremors1Stiffness1Cardiovascular ADRs12 (5.79%)Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia11Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Tremors1Stiffness1Cardiovascular ADRs12 (5.79%)Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Stiffness1Cardiovascular ADRs12 (5.79%)Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)	Headache	
Cardiovascular ADRs12 (5.79%)Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		1
Palpitation11Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Hypertension1Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)	Cardiovascular ADRs	
Respiratory system ADRs10 (4.83%)Dyspnoea7Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Dyspnoea7Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Chest pain2Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Hematological ADRs4 (1.93%)Thrombocytopenia3Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Thrombocytopenia3Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Pancytopenia1Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)		
Renal system ADRs-3 (1.44%)Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)	Thrombocytopenia	3
Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)	Pancytopenia	1
Hyperuricaemia2Uremia1Endocrine system ADRs1 (0.48%)	Renal system ADRs-	3 (1.44%)
Uremia 1   Endocrine system ADRs 1 (0.48%)		2
		1
Gynaecomastia 1	Endocrine system ADRs	1 (0.48%)
	Gynaecomastia	1

## Table 2: Suspected drugs causing ADRs.

ADRs	Value
Antimicrobial agents (antibiotics)	62 (29.95%)
Ceftriaxone	8
Piperacillin+tazobactum	7
Ciprofloxacin	6
Isoniazid+rifampicin	5
Amoxicillin+clavulanic acid	4
Pyrazinamide	3
Aztreonam	2
Tigecycline	2
Meropenem	2
Colistimethate sodium (Colistin)	2
Vancomycin	2
Teicoplanin	2
Linezolid	2
Polymyxin B	2
Cefuroxime	1
Clarithromycin	1
Lamivudine+tenofovir+efavirenz	1
Cefoperazone+sulbactam	1
Cefixime	1
Amphotericin B	1
Ticarcillin+clavulanic acid	1
Imipenem+cilastatin	1
Moxifloxacin	1
Fluconazole	1
Penicillin G	1
Voriconazole	1
Rifampicin	1
Drugs acting on central nervous system	41 (19.80%)
Pregabalin	6
Amitryptiline	4
Valproic acid	4
Gabapentine	4
Notriptyline	4
Oxcarbazepine	3
Phenytoin	3
Tramadol	2
Duloxetine	2
Levetiracetam	2
Cinnarizine	1
Topiramate	1
Vilazodone	1
Pyridostigmine	1
Mirtazapine	1
Buspirone	1
Mannitol	1
Chemotherapeutic agents (anti-cancer drugs)	24 (11.59%)
Paclitaxel	10
Rituximab	5
Oxaliplatin	3
5-Fluoro uracil	1
Carboplatin	1
Docetaxel	1
Etoposide	1
Erlocip	1
Entop	1
Gefitinib	1

Continued.

ADRs	Value
Nutritional supplements and electrolytes	19 (9.17%)
Human albumin	7
KCl	2
Celemin hepa	2
Normal Saline	2
Cobamamide	1
Pyridoxine	1
Evion	1
Folic acid	1
Vitamin D3	1
Ringer lactate	1
Cardiovascular drugs	16 (7.72%)
Amlodipine	4
Metoprolol	4
Rosuvastatin	2
Telmisartan	1
Amiodarone	1
Enalapril	1
Carvedilol	1
Atenolol	1
Ivabradine	1
Gastrointestinal drugs	1 14 (6.76%)
	5
Domperidone Ondansetrone	2
	1
Metoclopramide Bifilac	
	1
Raberprazole	1
Furazolidone	1
Dicyclomine	1
Metronidazole	1
Norfloxacin+tinidazole	1
Non-steroidal anti-inflammatory drugs	10 (4.83%)
Etoricoxib	5
Indomethacin	2
Aceclofenac	1
Paracetamol	1
Aspirin	1
Endocrine system drugs	10 (4.83%)
Levothyroxine	2
Ergocalciferol	2
Calcium carbonate	2
Dexamethasone	1
Canagliflozin	1
Megesterol	1
Metformin	1
Renal system drugs	4 (1.93%)
Spironolactone+torasemide	2
Furosemide+amiloride	1
Alfuzosin hydrochloride	1
Haematological system drugs	3 (1.44%)
Vitamin K (Phytomenadione)	1
Clopidogrel	1
Iron-Sucrose	1
Anti-histaminic drugs	3 (1.44%)
Hydroxyzine	1
Monteleukast+fexofenadine	1
Levocetrizine	1
Vaccine	1 (0.48%)
DPT	1

According to Rawlins and Thompson classification 74.87% ADRs (n=155) belonged to type A (augmented or predictable) category and 25.12% ADRs (n=52) belonged to type B (bizarre/unpredictable) category (Figure 3).<sup>10</sup>




Figure 3: Type of ADRs.

Oral route of drug administration accounts for 57% (n=118) ADRs, I.V. route for 42.51% (n=88) while I.M. route for only one ADR (n=1, 0.48%) out of total cases (Figure 4).




Figure 4: Route of drug administration.

For assessing the severity of ADRs, modified Hartwig and Siegel Scale was used.<sup>11</sup> According to this scale, maximum ADRs belonged to moderate category (n=111, 53.62%), mild category ADRs were 43.96% (n=91) while only 2.41 % ADRs (n=5) were severe (Figure 5).




Figure 5: Severity of ADR.

The WHO-UMC Causality Assessment Criteria was used for assessing causality of ADRs. According to this criteria, maximum ADRs (n=195, 94.20%) were probable 2.89% (n=6) were possible, 1.44% (n=3) were certain while 1.44% (n=3) were unlikely with the suspected drug (Figure 6).




Figure 6: Causality assessment of ADRs.

Most of the ADRs (97.58%, n=202) were non-serious while only 2.41% (n=5) were serious in nature. The patients who recovered from the ADR after taking appropriate steps like stopping the suspected drug were 59.90% (n=124), patients who did not recover at all were 39.61% (n=82) while 0.48% (n=1) one case was fatal which led to death of the patient.

# Table 3: Seriousness, outcome, and management of<br/>ADRs.

Serious: 5	Recovered: 124 (59.90%)	Suspected drugs stopped: 117 (56.52%)
-	Not-recovered: 82 (39.61%)	Suspected drugs stopped then re- started: 4 (1.93%)
Non-serious: 202 (97.58%)	Fatal (death): 1 (0.48%)	Suspected drugs not stopped: 86 (41.54%)

In 56.52% (n=117) cases, the suspected drug was stopped completely after ADR was noticed in 1.93% (n=4) cases, the suspected drug was restarted after stopping once the symptoms subsided while in 41.54% (n=86) cases the drug was not stopped and was continued after assessing the risk and benefit of the therapy as the ADR was less important than the benefit of the drug therapy for the patient (Table 3).

#### DISCUSSION

ADRs belong to one of the major causes of morbidity and mortality in hospital setup, but most of the cases remain below the tip of iceberg due to lack of reporting of such cases. This study was done to analyse the ADRs reported at AMC, retrospectively for the pattern and type of ADRs, causative drugs, demographic profile of patients, type and severity of ADRs and their causality assessment.

A total of 207 suspected ADR reports were received from various departments at our AMC over a period of 18 months, from September 2017 to February 2019. The pattern of gender distribution of these ADRs showed that male and female patients suffering from ADRs were almost equal, male (50.25%) and female (49.75%), which is just coincidental finding as several other studies showed male preponderance<sup>12-14</sup> while few studies showed female preponderance.<sup>15,16</sup> Thus, it is concluded that gender does not influence the ADRs due to drugs. The age group affected most commonly with ADRs were in the age range of 41-50 years (21.25%), as found in other studies also.<sup>17,18</sup> The age group most commonly involved also depends on the type of disease for which the patients are visiting particular hospital setup. As there are diseases which affect a particular age group and so the ADRs caused by such treatments will also affect only that particular age group of patients.

The organ system affected most commonly by ADRs was cutaneous reactions involving skin (44.44%) followed by generalized ADRs (25.12%) involving whole body and further followed by ADRs affecting gastrointestinal system (9.66%). Similar patterns were also found in other studies.<sup>19,20</sup>

The commonest ADRs reported by patients were rashes, itching, whole body discomfort, chills, rigors, vomiting, abdominal pain and diarrhoea which is also similar to other studies.<sup>21</sup>

The drugs most commonly suspected to be causing the ADRs belong to Antimicrobial agents (29.95%). Antibiotics like Penicillin and Cephalosporins were most commonly involved. This is followed by drugs acting on central nervous system (19.80%) like Antiepileptics and Antidepressants which is further followed by Anti-cancer drugs (11.59%) like Paclitaxel and Rituximab. These findings are in agreement to another similar study.<sup>22</sup> Patients given drugs by oral route were most commonly affected by ADRs (57%) in present study followed by I.V. route (42.51%) and I.M. route with only one case (0.48%). According to Rawlins and Thompson classification of ADRs, 74.87% ADRs belonged to Type A category while 25.12% ADRs were of Type B category. Majority of ADRs were non-serious (97.5%) and only 2.41% were serious, which is similar to another study.22

Most of the patients recovered from the ADRs (59.90%) while 39.61% patients did not recover at all and only one case (0.48%) was fatal which led to death of the patient. In 56.52% patients, the suspected drug was stopped in 1.93% cases it was restarted again after stopping, when the symptoms of ADR subsided while in 41.54% cases the drug was not stopped at all. According to modified

Hartwig and Siegel scale, 53.62% ADRs belonged to moderate category, 43.96% ADRs were of mild category while only 2.41% ADRs were severe. These patterns of ADRs were consistent with other similar studies.<sup>23,24</sup>

The causality of ADRs were assessed according to WHO-UMC causality assessment criteria and it was found that maximum ADRs were probable (94.20%), 2.89% were possible while only 1.44% belonged to both certain and unlikely category. These findings were similar to a study but different from results obtained in other studies.<sup>25,26</sup>

## Limitations

There are certain limitations of this study, most common being underreporting of ADRs by health care professionals (HCPs). Although we have conducted many sensitization programmes for increasing awareness among HCPs, but still under reporting remains the most important limitation of spontaneous reporting of ADRs.

Another limitation is short duration of study period because, after this duration our Pv associate was transferred to NCC, Ghaziabad due to some reasons. Lack of patient follow-up is another limitation.

So present results may not be generalized on large scale as the study was confined to our AMC only, still the findings will contribute to the pattern of ADRs reported in tertiary care hospitals.

## **CONCLUSION**

This study concluded that the age group most commonly affected by ADRs was in the age range of 41-50 years with equal frequency in both male and female gender, although these may be incidental findings. Cutaneous reactions like rashes and itching were the most commonly reported ADRs and antimicrobial agents like Penicillin and Cephalosporin group of antibiotics were the most common causative drugs leading to ADRs.

Drugs administered orally were most commonly involved in causing ADRs in this study. Most of the reactions were non-serious and moderate reactions in which the patient recovered from the symptoms of ADRs after stopping the suspected drugs. Only one case was fatal which led to death of the patient. Also, most of the reactions were Type A reactions and were probable with the suspected drugs.

This study apart from its few limitations, stresses on the need of an effective and robust pharmacovigilance system for ADR monitoring and also strongly suggests that ADR reporting concepts need to be enhanced among health care professionals, to safeguard public health.

Funding: No funding sources Conflict of interest: None declared Ethical approval: The study was approved by Institutional Ethics Committee

### REFERENCES

- Adverse drug reaction definition. Available at: http://www.who.int/medicines/areas/quality\_safety/sa fety\_efficacy/trainingcourses/definitions.pdf. Accessed on 25 January 2020.
- Arulmani R, Rajendran SD, Suresh B. Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharmacol. 2008;65:210-6.
- Pharmacovigilance definition. Available at: http://www.who.int/medicines/areas/quality\_safety/sa fety\_efficacy/pharmvigi/en/. Accessed on 25 January 2020.
- 4. Pharmacovigilance mission. Available at: https://ipc.gov.in//PvPI/about.html#menu2. Accessed on 03 January 2020.
- WHO collaborating centre for pharmacovigilance in public health programmes and regulatory services. Available at: https://www.who.int/medicines/ regulation/medicines-safety/about/collab-centresindia/en/ Accessed on 03 January 2020.
- ADR reporting form. Available at: http://www.ipc.gov.in/PvPI/adr.html. Assessed 25 January 2020.
- WHO causality assessment. Available at: https://www.who.int/medicines/areas/quality\_safety/s afety\_efficacy/WHOcausality\_assessment.pdf. Accessed on 25 January 2020.
- Vigiflow and Signal detection. Available at: https://ipc.gov.in//PvPI/about.html#menu2. Accessed on 25 January 2020.
- Mahajan's Methods In Biostatistics For Medical Students And Research Workers Paperback – 25 January 2020
- Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1991: 18-45.
- 11. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229-32.
- Lobo MG, Pinheiro SM, Castro JG, Momenté VG, Pranchevicius MC. Adverse drug reaction monitoring: Support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC Pharmacol Toxicol. 2013;14:5.
- 13. Dutta SB, Beg MA, Bawa S, Anjoom M, Varma A, Singh NK. A retrospective analysis of adverse drug reactions in a tertiary care teaching hospital at Dehradun, Uttarakhand. Int J Basic Clin Pharmacol. 2015;4(1):121-4.
- 14. Subbanna PK, Chandy SJ. The role of active surveillance in improving the hospital adverse drug event reporting. Indian J Pharmacol. 2006;38:363-4.
- 15. Miller MA. Gender-based differences in the toxicity of pharmaceuticals- the food and drug Administration's perspective. Int J Toxicol. 2001;20(3):149-52.

- Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a south Indian hospital- their severity and cost involved. Pharmacoepidemiol Drug Saf. 2003;12(8):687-92.
- 17. Kharb P, Mittal N, Gupta MC. An evaluation of adverse drug reactions monitoring at a pharmacovigilance unit under pharmacovigilance programme of India in a tertiary care hospital of Haryana. Int J Basic Clin Pharmacol. 2015;4:556-60.
- 18. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol. 2007;7:8
- Patidar D, Rajput MS, Nirmal NP, Savitri W. Implementation and evaluation of adverse drug reaction monitoring system in a tertiary care teaching hospital in Mumbai, India. Interdiscip Toxicol. 2013;6(1):41-6.
- Jose J. Rao PG. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res. 2006;54(3):226-33.
- 21. Caranasos GJ, Stewart RB, Cluff LE. Drug-induced illness leading to hospitalization. JAMA. 1974;228(6):713-7.
- 22. Sen M, Singh A, Misra M. Retrospective analysis of adverse drug reactions reported at ADR monitoring centre under PvPI in a tertiary care hospital. Int J Basic Clin Pharmacol. 2018;7:303-8.
- 23. Shareef SM, Naidu CDM, Raikar SR, Rao YV, Devika U. Development, implementation and analysis of adverse drug reaction monitoring system in a rural tertiary care teaching hospital in Narketpally, Telangana. Int J Basic Clin Pharmacol. 2015;4:757-60.
- 24. Vijayakumar TM, Dhanaraju MD. Description of adverse drug reactions in a multi-speciality teaching hospital. Int J Integr Med. 2013;1(26):1-6.
- 25. Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother. 2000;34(12):1373-9.
- 26. Murphy BM, Frigo LC. Development, implementation and results of a successful multidisciplinary adverse drug reaction reporting program in a university teaching hospital. Hosp Pharm. 1993;28(12):1199-204,1240.

**Cite this article as:** Singh A, Jain A, Soni M, Shukla P, Lahon J, Verma AK. Pattern of adverse drug reactions reported at a tertiary care teaching hospital in northern India. Int J Basic Clin Pharmacol 2020;9:625-32.